SOURCE: Vasuda Capital Management

December 03, 2015 10:00 ET

Rare Disease and Orphan Drug Biotechnology Indexes Launched

These Indexes Aim to Represent and Track the Aggressive Growth of These Lucrative Biotechnology Sub-Sectors

BOSTON, MA--(Marketwired - December 03, 2015) - Vasuda Indices, a subsidiary of Vasuda Capital Management, a Boston-based biotechnology focused investment management firm announced the launch of Vasuda Rare Disease Biotechnology Marvels Index and Vasuda Select Orphan Drug Breakthroughs Index. No other U.S. index tracks these lucrative biotechnology sub-sectors at present. In addition, the firm also sponsors Vasuda Emerging Oncology Breakthroughs Index that represents emerging growth companies with development pipeline in broad oncology treatment areas (not limited to just cancer immunotherapy). Further details of the indexes are available at www.vasudaindices.com.

"Rare disease, orphan drug and oncology therapy sub-sectors have historically out-performed the broad biotechnology sector due to the pricing power of these companies and M&A activity. We expect these indexes to be representative of these lucrative biotech sub-sectors," said Dr. Bhavneesh Sharma MD, who is the Principal and Investment Manager of Vasuda Indices and Vasuda Capital Management and also holds an MBA in finance from the New York University's Stern School of Business.

About Vasuda Indices and Vasuda Capital Management: Vasuda Indices, LLC is a wholly owned subsidiary of Vasuda Capital Management, a Greater Boston-based biotechnology-focused investment management firm. The firm was founded by Dr. Bhavneesh Sharma, a physician with an MBA in finance from the New York University's Stern School of Business.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Vasuda Indices and Vasuda Capital Management undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Contact Information